Answers are grounded in this paper and cite their sources.
Purpose Standardised international reporting for colon cancer (CC) provides foundational prognostic data. However, novel histopathological variables—tumour-infiltrating lymphocytes (TILs), tumour budding (TB), and poorly differentiated clusters (PDCs)—offer superior insights into tumour biology. This review evaluates their clinical utility in risk stratification and treatment personalisation for stage I–III CC. Methods A comprehensive literature review was conducted to evaluate the prognostic and predictive value of TILs, TB, and PDCs in stage I–III CC. Results High TIL density is associated with improved oncological endpoints in stage II–III disease. Crucially, in stage III disease, a high Immunoscore predicts a survival benefit from extending adjuvant chemotherapy from 3 to 6 months, whereas low TIL density in mismatch repair deficient may identify a high-risk patient cohort that is otherwise overlooked. Conversely, high-grade (HG) TB and PDCs are potent independent markers of poor prognosis, outperforming traditional histopathological variables in multiple studies. In stage I disease, HG TB/PDCs significantly elevate the risk of lymph node metastasis, providing a critical metric when considering segmental resection after malignant polyp removal. In the stage II/III cohort, HG TB/PDCs correlate with diminished disease-free and overall survival, with emerging data suggesting these variables may identify phenotypes resistant to standard fluoropyrimidine monotherapy. Conclusion TILs, TB, and PDCs provide vital, biology-focused prognostic and predictive data using cost-effective, routinely stained sections of tumour. Incorporating these variables into standard synoptic reporting and clinical guidelines will refine risk stratification and advance precision oncology in CC management.
No takes yet. Share an insight, caveat, or question.
Davis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: